The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis, Qualcomm joint venture backs $6.5M Series A round for Science 37

The joint venture set up by Novartis and Qualcomm has teamed up with Lux Capital to funnel $6.5 million into Science 37. Los Angeles, CA-based Science 37 will use the cash to step up the expansion of its virtual, tech-enabled model of clinical trial services.

J&J inks deal to access Nuevolution's informatics-enabled discovery platform

Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.

Novartis inks a string of deals to widen its immuno-oncology arsenal

Novartis, developing cancer treatments that tap the power of the immune system, signed a pair of agreements to pad its pipeline of new oncology therapies, planning to test them alone and in tandem with in-house assets.

Gamida Cell pockets $5M from Novartis ahead of mooted financing round

Novartis has come good on its promise to continue collaborating with Gamida Cell despite twice walking away from takeover agreements. The Big Pharma handed over $5 million (€4.4 million) for a 2.5% stake in Gamida Cell this week--and promised to invest a further $10 million if its collaborator wraps up an equity financing by the end of 2017.

FierceMedicalDevices' 2015 Fierce 15

This year's Fierce 15 companies are all working on big ideas such as cutting-edge patient monitoring, smartphone-based imaging, biodegradable valves and vessels, more accurate knee implants, intestinal ablation to treat diabetes, energy-delivering angioplasty balloons, an implantable cell-based pancreas replacement, and connected asthma inhalers as well as the consumerization of health devices and diagnostics.

Novartis buys a bigger stake in Gamida, stopping short of a $600M plunge

Novartis is acquiring more of stem cell partner Gamida Cell but steering away from buying the company outright as it blueprints a Phase III trial for its blood cancer therapy.

Early Gilenya generics now spell trouble for rival MS drugs

Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.

Novartis targets Amgen's Enbrel with second biosimilar app

Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.

Novartis comes for Enbrel in latest biosimilar shot at Amgen

A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.

Facing a crisis, Xoma buys time with a $517M Novartis deal

Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.